{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T03:33:12Z","timestamp":1758943992382,"version":"3.28.0"},"reference-count":28,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004023","type":"journal-article","created":{"date-parts":[[2003,11,21]],"date-time":"2003-11-21T22:16:55Z","timestamp":1069453015000},"update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Early versus deferred treatment for early stage multiple myeloma"],"prefix":"10.1002","volume":"2012","author":[{"given":"Yulong","family":"He","sequence":"first","affiliation":[{"name":"Biomedicum Helsinki, University of Helsinki; Molecular\/Cancer Biology Laboratory and Ludwig Institute for Cancer Research; Haartmaninkatu 8 Helsinki Finland 00014"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Wheatley","sequence":"additional","affiliation":[{"name":"University of Birmingham; Cancer Research UK Clinical Trials Unit, School of Cancer Sciences; Edgbaston Birmingham UK B15 2TT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Glasmacher","sequence":"additional","affiliation":[{"name":"University of Bonn; Bonn Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamish","family":"Ross","sequence":"additional","affiliation":[{"name":"Northampton General Hospital NHS Trust; Cliftonville Northampton UK NN1 5BD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Djulbegovic","sequence":"additional","affiliation":[{"name":"Center for Evidence Based Medicine and Health Outcomes Research, University of South Florida; Professor of Medicine and Oncology, H. Lee Moffitt Cancer Center; USF Health Clinical Research, 12901 Bruce B. Downs Boulevard, MDC02 Tampa Florida USA 33612"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,1,20]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD004023-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden","volume":"50","author":"Hjorth","year":"1993","journal-title":"European Journal of Haematology"},{"issue":"6","key":"10.1002\/14651858.CD004023-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/bjc.1994.474","article-title":"Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma","volume":"70","author":"Riccardi","year":"1994","journal-title":"British Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD004023-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1054\/bjoc.1999.1087","article-title":"Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma","volume":"82","author":"Riccardi","year":"2000","journal-title":"British Journal of Cancer"},{"issue":"7","key":"10.1002\/14651858.CD004023-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJM199402173300709","article-title":"The treatment of multiple myeloma","volume":"330","author":"Alexanian","year":"1994","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD004023-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-134-8-200104170-00012","article-title":"The revised CONSORT statement for reporting randomized trials: explanation and elaboration","volume":"134","author":"Altman","year":"2001","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD004023-BIB0006|cit6","first-page":"317","article-title":"NCCN practice guidelines for multiple myeloma.","volume":"12","author":"Anderson","year":"1998","journal-title":"Oncology"},{"issue":"2","key":"10.1002\/14651858.CD004023-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004023-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1590\/S1516-31801997000300004","article-title":"Optimal search strategy for clinical trials in the Latin Anerican and Caribbean Health Science Literature Database (LILIACS).","volume":"115","author":"Castro","year":"1997","journal-title":"Revista paulista de medicina"},{"key":"10.1002\/14651858.CD004023-BIB0009|cit9","article-title":"Cochrane Reviewer's Handbook 4.1 [update July 2000]","volume-title":"Oxford: The Cochrane Collaboration; Review Manager (Revman) 4.1","author":"Clarke","year":"1999"},{"issue":"9","key":"10.1002\/14651858.CD004023-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1200\/JCO.1986.4.9.1331","article-title":"Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study","volume":"4","author":"Cooper","year":"1986","journal-title":"Journal of Clinical Oncology"},{"issue":"6964","key":"10.1002\/14651858.CD004023-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"Bmj"},{"key":"10.1002\/14651858.CD004023-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1023\/A:1013181331874","article-title":"Evaluation and appraisal of randomized controlled trials in myeloma.","volume":"12","author":"Djulbegovic","year":"2001","journal-title":"Ann Oncology"},{"key":"10.1002\/14651858.CD004023-BIB0013|cit13","first-page":"251a","article-title":"Database for health outcomes and quality of randomized trials in multiple myeloma","volume":"21","author":"Djulbegovic","year":"2002","journal-title":"Proceeding of American Society of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD004023-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD004023-BIB0015|cit15","first-page":"87","article-title":"Systematic reviews in health care.","volume":"2nd ed.","author":"Egger","year":"2001","journal-title":"London: BMJ Books"},{"issue":"1","key":"10.1002\/14651858.CD004023-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V54.1.13.13","article-title":"Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB","volume":"54","author":"Harley","year":"1979","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD004023-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3949\/ccjm.61.4.285","article-title":"Multiple myeloma: an overview of diagnosis and management","volume":"61","author":"Hussein","year":"1994","journal-title":"Cleveland Clinic Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004023-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD004023-BIB0019|cit19","article-title":"Randomized Controlled Trials.","volume-title":"London: BMJ Books","author":"Jadad","year":"1998"},{"issue":"7303","key":"10.1002\/14651858.CD004023-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"Juni","year":"2001","journal-title":"Bmj"},{"issue":"1","key":"10.1002\/14651858.CD004023-BIB0021|cit21","first-page":"6","article-title":"Cancer statistics, 1998","volume":"48","author":"Landis","year":"1998","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"12","key":"10.1002\/14651858.CD004023-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","article-title":"Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group","volume":"16","author":"Myeloma Trialists' Collaborative Group","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD004023-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004023-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"580-93; discuss","DOI":"10.1016\/S0197-2456(97)00051-2","article-title":"Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis","volume":"18","author":"Pogue","year":"1997","journal-title":"Controlled Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD004023-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/ije\/31.1.150","article-title":"Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed","volume":"31","author":"Robinson","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD004023-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.1983.1.8.453","article-title":"Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study","volume":"1","author":"Salmon","year":"1983","journal-title":"Journal of Clinical Oncology"},{"issue":"9265","key":"10.1002\/14651858.CD004023-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(00)04522-0","article-title":"Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours","volume":"357","author":"Shakespeare","year":"2001","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD004023-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0895-4356(98)00131-0","article-title":"The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus","volume":"51","author":"Verhagen","year":"1998","journal-title":"Journal of Clinical Epidemiology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD004023\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T18:47:03Z","timestamp":1730227623000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004023"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2003,1,20]]},"references-count":28,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004023","relation":{},"ISSN":["1465-1858"],"issn-type":[{"type":"electronic","value":"1465-1858"}],"subject":[],"published":{"date-parts":[[2003,1,20]]}}}